
Novo and Pivotal BioVenture Partners both invested as the lung disease therapy developer took its overall funding close to $100m.
Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.
Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.
Otsuka Pharmaceuticals's McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.
Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.
Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
GV, AbbVie Ventures and NS Investment have contributed to a series B round for the oncology drug developer, which has now raised a total of $103m.
The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.
Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.